Tirzepatide dosing for weight loss follows a stepwise titration: start at 2.5 mg once weekly for 4 weeks, then increase by 2.5 mg every 4 weeks to reach a maintenance dose of 5, 10, or 15 mg. This schedule, set in the FDA-approved label for Zepbound, minimizes GI side effects while delivering the 15–20% weight loss seen in pivotal trials.
What Tirzepatide Is and How It Works
Tirzepatide is a once-weekly injection that activates both GLP-1 and GIP receptors—two gut hormones that reduce appetite, slow gastric emptying, and improve insulin sensitivity. It is sold as Zepbound for chronic weight management and Mounjaro for type 2 diabetes.
Per the SURMOUNT-1 trial in the New England Journal of Medicine, participants at 15 mg lost an average 20.9% body weight over 72 weeks—closer to bariatric surgery results than traditional weight-loss drugs.
The FDA Titration Schedule
| Weeks | Dose | Notes |
|---|---|---|
| 1–4 | 2.5 mg | Starting dose; not for maintenance |
| 5–8 | 5 mg | First maintenance option |
| 9–12 | 7.5 mg | Titration step |
| 13–16 | 10 mg | Second maintenance option |
| 17–20 | 12.5 mg | Titration step |
| 21+ | 15 mg | Maximum maintenance dose |
Clinicians may slow the pace if side effects persist. According to the FDA prescribing information, each dose should be taken for at least 4 weeks before escalating.
Weight Loss Expectations at Each Dose
From SURMOUNT-1 at 72 weeks:
- 5 mg: ~15.0% weight loss
- 10 mg: ~19.5% weight loss
- 15 mg: ~20.9% weight loss
- Placebo: ~3.1%
Most people see noticeable appetite suppression within 1–2 weeks of starting and measurable weight change by 4–8 weeks. Plateaus are common between dose increases.
Who Is a Candidate
Zepbound is approved for adults with:
- BMI of 30 or higher, OR
- BMI of 27 or higher plus a weight-related condition (hypertension, dyslipidemia, type 2 diabetes, sleep apnea, cardiovascular disease)
People with prediabetes often qualify under the comorbidity route. Learn more on our treatment hub.
Side Effects and How to Manage Them
Common (10%+)
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Abdominal pain
- Fatigue, injection-site reactions
GI effects concentrate in the first week after each dose bump. Smaller meals, protein-first eating, and hydration help most.
Rare but Serious
- Pancreatitis
- Gallbladder disease
- Kidney injury (often dehydration-related)
- Severe hypoglycemia when combined with insulin or sulfonylureas
- Allergic reactions
The FDA carries a boxed warning for thyroid C-cell tumors based on rat studies. Do not use if you have a personal or family history of medullary thyroid carcinoma or MEN 2.
Practical Tips for Titration
- Inject on the same day each week; rotate sites (abdomen, thigh, upper arm).
- Stay hydrated—kidney issues in trials tied to dehydration.
- Eat protein-forward, smaller meals for the first week after an increase.
- Keep a symptom log to share at your next visit.
- Do not double up a missed dose; consult the prescribing information for timing.
Tirzepatide for Prediabetes
Tirzepatide is not FDA-approved specifically for prediabetes, but people with prediabetes frequently qualify for Zepbound based on BMI and comorbidities. In type 2 diabetes trials, the drug lowered A1C by 1.6–2.4%—a large effect that translates meaningfully to prediabetes populations too.
Beyond medication, the CDC’s Diabetes Prevention Program shows that losing 5–7% of body weight with lifestyle change alone cuts diabetes risk by 58%. Tirzepatide accelerates the weight-loss piece; lifestyle change sustains it. Our prediabetes 101 hub covers the full playbook.
Cost, Coverage, and Access
List price for Zepbound is roughly $1,060 per month. Commercial insurance coverage varies; savings cards can bring it to $25 for eligible patients. Medicare does not typically cover weight-loss drugs. Eli Lilly launched a self-pay program in 2024 with prefilled vials at reduced prices for those without coverage.
When to Step Down or Stop
Side effects that don’t resolve at a given dose warrant stepping back, not pushing through. Pregnancy, planned surgery, or severe GI illness are reasons to pause. Stopping abruptly usually leads to significant weight regain, so plan transitions with your clinician.
The Bottom Line
Tirzepatide dosing for weight loss follows a predictable monthly titration from 2.5 mg to a maintenance dose of 5, 10, or 15 mg. The schedule exists to limit side effects, and skipping ahead is counterproductive. Weight loss expectations are substantial—but sustainability depends on long-term use paired with lifestyle change.
This article is educational and not a substitute for personalized medical advice. Always consult your healthcare provider about symptoms, testing, and treatment.
